Top

Current Cardiovascular Imaging Reports

Published in:

01-04-2020 | Edema | Cardiac Magnetic Resonance (E Nagel and V Puntmann, Section Editors)

CMR in Hypertrophic Cardiac Conditions—an Update

Authors: Michalis Kolentinis, Viviana Maestrini, Eleftherios Vidalakis, Sara Cimino, Luca Arcari

Published in: Current Cardiovascular Imaging Reports | Issue 4/2020

Abstract

Purpose of Review

Myocardial left ventricular (LV) hypertrophy (LVH) is a common phenotype associated to increased morbidity and mortality. Beyond an accurate LV mass quantification, cardiovascular magnetic resonance (CMR) can also provide tissue characterization, perfusion, and deformation assessments. Aim of the present review is to discuss recent advances in CMR imaging of LVH.

Recent Findings

T1 and T2 mapping techniques expanded the ability of CMR in phenotyping LVH, underscoring the pathogenic significance of interstitial fibrosis and edema in hypertrophic conditions. Perfusion and deformation assessments revealed dysfunctional correlates not uncommonly associated to LVH. Late gadolinium enhancement (LGE) highlighted the role of replacement fibrosis as a marker of advanced disease. Finally, the prognostic relevance of both interstitial and replacement fibrosis has been demonstrated in several LVH conditions.

Summary

CMR is an efficient tool for differential diagnosis of LVH phenotypes. Furthermore, it can often provide prognostic information, potentially guiding treatment and improving clinical management.

Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561–6. https://doi.org/10.1056/NEJM199005313222203.CrossRefPubMed

Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson. 2013;15:35. https://doi.org/10.1186/1532-429X-15-35.CrossRefPubMedPubMedCentral

Scatteia A, Baritussio A, Bucciarelli-Ducci C. Strain imaging using cardiac magnetic resonance. Heart Fail Rev. 2017;22:465–76. https://doi.org/10.1007/s10741-017-9621-8.CrossRefPubMedPubMedCentral

Nagel E, Greenwood JP, McCann GP, Bettencourt N, Shah AM, Hussain ST, et al. Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl J Med. 2019;380:2418–28. https://doi.org/10.1056/NEJMoa1716734.CrossRefPubMed

Arcari L, Bucciarelli-Ducci C, Francone M, Agati L. Myocardial salvage imaging: where are we and where are we heading? A cardiac magnetic resonance perspective. Curr Cardiovasc Imaging Rep. 2018;11:8–8. https://doi.org/10.1007/s12410-018-9448-2.CrossRef

Puntmann VO, Peker E, Chandrashekhar Y, Nagel E. T1 mapping in characterizing myocardial disease. Circ Res. 2016;119:277–99. https://doi.org/10.1161/CIRCRESAHA.116.307974.CrossRefPubMed

Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445–53. https://doi.org/10.1056/NEJM200011163432003.CrossRefPubMed

Puntmann VO, Valbuena S, Hinojar R, Petersen SE, Greenwood JP, Kramer CM, et al. Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part i - analytical validation and clinical qualification. J Cardiovasc Magn Reson. 2018;20:1–23. https://doi.org/10.1186/s12968-018-0484-5.CrossRef

[9•.

] Rodrigues JCL, Amadu AM, Dastidar AG, Szantho GV, Lyen SM, Godsave C, et al. Comprehensive characterisation of hypertensive heart disease left ventricular phenotypes. Heart. 2016;102:1671–9. https://doi.org/10.1136/heartjnl-2016-309576This study undertakes a comprehensive characterization of LVH in HTN patients, including interstitial fibrosis assessment and an interesting subgroup analysis according to specific LVH morphology. CrossRefPubMed

[10]

Neisius U, Myerson L, Fahmy AS, Nakamori S, El-Rewaidy H, Joshi G, et al. Cardiovascular magnetic resonance feature tracking strain analysis for discrimination between hypertensive heart disease and hypertrophic cardiomyopathy. PLoS One. 2019;14:e0221061. https://doi.org/10.1371/journal.pone.0221061.CrossRefPubMedPubMedCentral

[11]

Homsi R, Kuetting D, Sprinkart A, Steinfeld N, Meier-Schroers M, Luetkens J, et al. Interrelations of epicardial fat volume, left ventricular T1-relaxation times and myocardial strain in hypertensive patients: a cardiac magnetic resonance study. J Thorac Imaging. 2017;32:169–75. https://doi.org/10.1097/RTI.0000000000000264.CrossRefPubMed

[12]

Bönner F, Janzarik N, Jacoby C, Spieker M, Schnackenburg B, Range F, et al. Myocardial T2 mapping reveals age- and sex-related differences in volunteers. J Cardiovasc Magn Reson. 2015;17:9. https://doi.org/10.1186/s12968-015-0118-0.CrossRefPubMedPubMedCentral

[13]

Treibel TA, Zemrak F, Sado DM, Banypersad SM, White SK, Maestrini V, et al. Extracellular volume quantification in isolated hypertension - changes at the detectable limits? J Cardiovasc Magn Reson. 2015;17:74. https://doi.org/10.1186/s12968-015-0176-3.CrossRefPubMedPubMedCentral

[14]

Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu C-Y, et al. T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy CLINICAL PERSPECTIVE. Circ Cardiovasc Imaging. 2015;8:e003285. https://doi.org/10.1161/CIRCIMAGING.115.003285.CrossRefPubMed

[15]

Pan JA, Michaëlsson E, Shaw PW, Kuruvilla S, Kramer CM, Gan L-M, et al. Extracellular volume by cardiac magnetic resonance is associated with biomarkers of inflammation in hypertensive heart disease. J Hypertens. 2018;37:1. https://doi.org/10.1097/HJH.0000000000001875.CrossRef

[16]

Coelho-Filho OR, Shah RV, Neilan TG, Mitchell R, Moreno H, Kwong R, et al. Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone. J Am Heart Assoc. 2014;3:e000790. https://doi.org/10.1161/JAHA.114.000790.CrossRefPubMedPubMedCentral

[17]

Kuruvilla S, Janardhanan R, Antkowiak P, Keeley EC, Adenaw N, Brooks J, et al. Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone. JACC Cardiovasc Imaging. 2015;8:172–80. https://doi.org/10.1016/j.jcmg.2014.09.020.CrossRefPubMedPubMedCentral

[18]

Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V, Quarta G, et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart. 2012;98:1436–41. https://doi.org/10.1136/heartjnl-2012-302346.CrossRefPubMed

[19]

Schofield R, Ganeshan B, Fontana M, Nasis A, Castelletti S, Rosmini S, et al. Texture analysis of cardiovascular magnetic resonance cine images differentiates aetiologies of left ventricular hypertrophy. Clin Radiol. 2019;74:140–9. https://doi.org/10.1016/j.crad.2018.09.016.CrossRefPubMed

[20]

Delacroix S, Chokka RG, Nelson AJ, Wong DT, Pederson S, Nimmo J, et al. Effects of renal sympathetic denervation on myocardial structure, function and perfusion: a serial CMR study. Atherosclerosis. 2018;272:207–15. https://doi.org/10.1016/j.atherosclerosis.2018.03.022.CrossRefPubMed

[21]

Rodrigues JCL, Rohan S, Ghosh Dastidar A, Harries I, Lawton CB, Ratcliffe LE, et al. Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness ≥ 15 mm. Eur Radiol. 2017;27:1125–35. https://doi.org/10.1007/s00330-016-4468-2.CrossRefPubMed

[22]

Singh A, McCann GP. Cardiac magnetic resonance imaging for the assessment of aortic stenosis. Heart. 2019;105:489–97. https://doi.org/10.1136/heartjnl-2018-313003.CrossRefPubMed

[23]

Podlesnikar T, Delgado V, Bax JJ. Cardiovascular magnetic resonance imaging to assess myocardial fibrosis in valvular heart disease. Int J Card Imaging. 2018;34:97–112. https://doi.org/10.1007/s10554-017-1195-y.CrossRef

[24]

Al MT, Uddin A, Swoboda PP, Fairbairn TA, Dobson LE, Singh A, et al. Cardiovascular magnetic resonance evaluation of symptomatic severe aortic stenosis: association of circumferential myocardial strain and mortality. J Cardiovasc Magn Reson. 2017;19:13. https://doi.org/10.1186/s12968-017-0329-7.CrossRef

[25]

Fehrmann A, Treutlein M, Rudolph T, Rudolph V, Weiss K, Giese D, et al. Myocardial T1 and T2 mapping in severe aortic stenosis: potential novel insights into the pathophysiology of myocardial remodelling. Eur J Radiol. 2018;107:76–83. https://doi.org/10.1016/j.ejrad.2018.08.016.CrossRefPubMed

[26]

Gastl M, Behm P, Haberkorn S, Holzbach L, Veulemans V, Jacoby C, et al. Role of T2 mapping in left ventricular reverse remodeling after TAVR. Int J Cardiol. 2018;266:262–8. https://doi.org/10.1016/j.ijcard.2018.02.029.CrossRefPubMed

[27]

Child N, Suna G, Dabir D, Yap M-L, Rogers T, Kathirgamanathan M, et al. Comparison of MOLLI, shMOLLLI, and SASHA in discrimination between health and disease and relationship with histologically derived collagen volume fraction. Eur Heart J Cardiovasc Imaging. 2018;19:768–76. https://doi.org/10.1093/ehjci/jex309.CrossRefPubMed

[28]

Bing R, Cavalcante JL, Everett RJ, Clavel M-A, Newby DE, Dweck MR. Imaging and impact of myocardial fibrosis in aortic stenosis. JACC Cardiovasc Imaging. 2019;12:283–96. https://doi.org/10.1016/j.jcmg.2018.11.026.CrossRefPubMedPubMedCentral

[29]

Chin CWL, Everett RJ, Kwiecinski J, Vesey AT, Yeung E, Esson G, et al. Myocardial fibrosis and cardiac decompensation in aortic stenosis. JACC Cardiovasc Imaging. 2017;10:1320–33. https://doi.org/10.1016/j.jcmg.2016.10.007.CrossRefPubMedPubMedCentral

[30]

Lee H, Park J-B, Yoon YE, Park E-A, Kim H-K, Lee W, et al. Noncontrast myocardial T1 mapping by cardiac magnetic resonance predicts outcome in patients with aortic stenosis. JACC Cardiovasc Imaging. 2018;11:974–83. https://doi.org/10.1016/j.jcmg.2017.09.005.CrossRefPubMed

[31•.

] Hwang I-C, Kim H-K, Park J-B, Park E-A, Lee W, Lee S-P, et al. Aortic valve replacement-induced changes in native T1 are related to prognosis in severe aortic stenosis: T1 mapping cardiac magnetic resonance imaging study. Eur Heart J Cardiovasc Imaging. 2019. https://doi.org/10.1093/ehjci/jez201Interesting study demonstrating the ability of native T1 to both track reverse remodeling and predict outcome after treatment of aortic stenosis, indicating that native T1 could be used as an imaging biomarker in this setting.

[32]

Ahn J-H, Kim SM, Park S-J, Jeong DS, Woo M-A, Jung S-H, et al. Coronary microvascular dysfunction as a mechanism of angina in severe AS. J Am Coll Cardiol. 2016;67:1412–22. https://doi.org/10.1016/j.jacc.2016.01.013.CrossRefPubMed

[33]

Singh A, Greenwood JP, Berry C, Dawson DK, Hogrefe K, Kelly DJ, et al. Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of MIcrovascular Dysfunction in Aortic Stenosis (PRIMID AS) Study. Eur Heart J. 2017;38:1222–9. https://doi.org/10.1093/eurheartj/ehx001.CrossRefPubMedPubMedCentral

[34]

Dweck MR, Joshi S, Murigu T, Alpendurada F, Jabbour A, Melina G, et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol. 2011;58:1271–9. https://doi.org/10.1016/j.jacc.2011.03.064.CrossRefPubMed

[35]

Barone-Rochette G, Piérard S, De Meester De Ravenstein C, Seldrum S, Melchior J, Maes F, et al. Prognostic significance of LGE by CMR in aortic stenosis patients undergoing valve replacement. J Am Coll Cardiol. 2014;64:144–54. https://doi.org/10.1016/j.jacc.2014.02.612.CrossRefPubMed

[36••.

] Musa TA, Treibel TA, Vassiliou VS, Captur G, Singh A, Chin C, et al. Myocardial scar and mortality in severe aortic stenosis. Circulation. 2018;138:1935–47. https://doi.org/10.1161/CIRCULATIONAHA.117.032839This multicenter study, with a notable sample size, underscores the prognostic significance of LGE presence, both ischemic and mid-wall, in patients with severe aortic stenosis. This propmpts the hypothesis that, in severe aortic stenosis, replacement fibrosis could be used as a marker of advanced disease requiring intervention irrespective of symptoms. CrossRefPubMedPubMedCentral

[37]

Everett RJ, Tastet L, Clavel M-A, Chin CWL, Capoulade R, Vassiliou VS, et al. Progression of hypertrophy and myocardial fibrosis in aortic stenosis. Circ Cardiovasc Imaging. 2018;11:e007451. https://doi.org/10.1161/CIRCIMAGING.117.007451.CrossRefPubMedPubMedCentral

[38]

Papanastasiou CA, Kokkinidis DG, Kampaktsis PN, Bikakis I, Cunha DK, Oikonomou EK, et al. The prognostic role of late gadolinium enhancement in aortic stenosis. JACC Cardiovasc Imaging. 2019. https://doi.org/10.1016/j.jcmg.2019.03.029.

[39]

Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52:559–66. https://doi.org/10.1016/j.jacc.2008.04.047.CrossRefPubMed

[40]

Musumeci MB, Russo D, Limite LR, Canepa M, Tini G, Casenghi M, et al. Long-term left ventricular remodeling of patients with hypertrophic cardiomyopathy. Am J Cardiol. 2018;122:1924–31. https://doi.org/10.1016/j.amjcard.2018.08.041.CrossRefPubMed

[41]

Hinojar R, Fernández-Golfín C, González-Gómez A, Rincón LM, Plaza-Martin M, Casas E, et al. Prognostic implications of global myocardial mechanics in hypertrophic cardiomyopathy by cardiovascular magnetic resonance feature tracking. Relations to left ventricular hypertrophy and fibrosis. Int J Cardiol. 2017;249:467–72. https://doi.org/10.1016/j.ijcard.2017.07.087.CrossRefPubMed

[42]

Vigneault DM, Yang E, Jensen PJ, Tee MW, Farhad H, Chu L, et al. Left ventricular strain is abnormal in preclinical and overt hypertrophic cardiomyopathy: cardiac MR feature tracking. Radiology. 2019;290:640–8. https://doi.org/10.1148/radiol.2018180339.CrossRefPubMed

[43]

Shi R, An D, Chen B, Wu R, Wu C, Du L, et al. High T2-weighted signal intensity is associated with myocardial deformation in hypertrophic cardiomyopathy. Sci Rep. 2019;9:2644. https://doi.org/10.1038/s41598-019-39456-z.CrossRefPubMedPubMedCentral

[44]

Abdel-Aty H, Cocker M, Strohm O, Filipchuk N, Friedrich MG. Abnormalities in T2-weighted cardiovascular magnetic resonance images of hypertrophic cardiomyopathy: regional distribution and relation to late gadolinium enhancement and severity of hypertrophy. J Magn Reson Imaging. 2008;28:242–5. https://doi.org/10.1002/jmri.21381.CrossRefPubMed

[45]

Todiere G, Pisciella L, Barison A, Del Franco A, Zachara E, Piaggi P, et al. Abnormal T2-STIR magnetic resonance in hypertrophic cardiomyopathy: a marker of advanced disease and electrical myocardial instability. PLoS One. 2014;9:e111366. https://doi.org/10.1371/journal.pone.0111366.CrossRefPubMedPubMedCentral

[46]

Hen Y, Takara A, Iguchi N, Utanohara Y, Teraoka K, Takada K, et al. High signal intensity on T2-weighted cardiovascular magnetic resonance imaging predicts life-threatening arrhythmic events in hypertrophic cardiomyopathy patients. Circ J. 2018;82:1062–9. https://doi.org/10.1253/circj.CJ-17-1235.CrossRefPubMed

[47]

Amano Y, Yanagisawa F, Tachi M, Hashimoto H, Imai S, Kumita S. Myocardial T2 mapping in patients with hypertrophic cardiomyopathy. J Comput Assist Tomogr. 2017;41:344–8. https://doi.org/10.1097/RCT.0000000000000521.CrossRefPubMed

[48]

McLellan A, Ellims AH, Prabhu S, Voskoboinik A, Iles LM, Hare JL, et al. Diffuse ventricular fibrosis on cardiac magnetic resonance imaging associates with ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2016;27:571–80. https://doi.org/10.1111/jce.12948.CrossRefPubMed

[49]

Avanesov M, Münch J, Weinrich J, Well L, Säring D, Stehning C, et al. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR. Eur Radiol. 2017;27:5136–45. https://doi.org/10.1007/s00330-017-4869-x.CrossRefPubMed

[50]

Gastl M, Gotschy A, von Spiczak J, Polacin M, Bönner F, Gruner C, et al. Cardiovascular magnetic resonance T2* mapping for structural alterations in hypertrophic cardiomyopathy. Eur J Radiol Open. 2019;6:78–84. https://doi.org/10.1016/j.ejro.2019.01.007.CrossRefPubMedPubMedCentral

[51]

Ariga R, Tunnicliffe EM, Manohar SG, Mahmod M, Raman B, Piechnik SK, et al. Identification of myocardial disarray in patients with hypertrophic cardiomyopathy and ventricular arrhythmias. J Am Coll Cardiol. 2019;73:2493–502. https://doi.org/10.1016/j.jacc.2019.02.065.CrossRefPubMedPubMedCentral

[52]

Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35:36–44. https://doi.org/10.1016/S0735-1097(99)00492-1.CrossRefPubMed

[53]

Yin L, Xu H, Zheng S, Zhu Y, Xiao J, Zhou W, et al. 3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy. Int J Card Imaging. 2017;33:1949–59. https://doi.org/10.1007/s10554-017-1189-9.CrossRef

[54]

Villa ADM, Sammut E, Zarinabad N, Carr-White G, Lee J, Bettencourt N, et al. Microvascular ischemia in hypertrophic cardiomyopathy: new insights from high-resolution combined quantification of perfusion and late gadolinium enhancement. J Cardiovasc Magn Reson. 2015;18:4. https://doi.org/10.1186/s12968-016-0223-8.CrossRef

[55]

Xu H, Yang Z, Sun J, Wen L, Zhang G, Zhang S, et al. The regional myocardial microvascular dysfunction differences in hypertrophic cardiomyopathy patients with or without left ventricular outflow tract obstruction: assessment with first-pass perfusion imaging using 3.0-T cardiac magnetic resonance. Eur J Radiol. 2014;83:665–72. https://doi.org/10.1016/j.ejrad.2014.01.008.CrossRefPubMed

[56]

Hinojar R, Zamorano JL, Gonzalez Gómez A, Plaza Martin M, Esteban A, Rincón LM, et al. ESC sudden-death risk model in hypertrophic cardiomyopathy: incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients. Clin Cardiol. 2017;40:853–60. https://doi.org/10.1002/clc.22735.CrossRefPubMedPubMedCentral

[57]

Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of LGE-CMR in HCM. JACC Cardiovasc Imaging. 2016;9:1392–402. https://doi.org/10.1016/j.jcmg.2016.02.031.CrossRefPubMed

[58]

Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130:484–95. https://doi.org/10.1161/CIRCULATIONAHA.113.007094.CrossRefPubMed

[59]

Briasoulis A, Mallikethi-Reddy S, Palla M, Alesh I, Afonso L. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart. 2015;101:1406–11. https://doi.org/10.1136/heartjnl-2015-307682.CrossRefPubMed

[60••.

] Freitas P, Ferreira AM, Arteaga-Fernández E, de Oliveira Antunes M, Mesquita J, Abecasis J, et al. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death. J Cardiovasc Magn Reson. 2019;21:50. https://doi.org/10.1186/s12968-019-0561-4This recent study highlights the prognostic relevance of LGE extent, rather than LGE presece alone, in predicting one of the most fearsome complication of HCM. CrossRefPubMedPubMedCentral

[61]

Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641–54. https://doi.org/10.1016/S0140-6736(15)01274-X.CrossRefPubMed

[62]

Pozo E, Kanwar A, Deochand R, Castellano JM, Naib T, Pazos-López P, et al. Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis. Heart. 2014;100:1688–95. https://doi.org/10.1136/heartjnl-2014-305710.CrossRefPubMed

[63]

Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70:466–77. https://doi.org/10.1016/j.jacc.2017.05.053.CrossRefPubMed

[64]

Williams LK, Forero JF, Popovic ZB, Phelan D, Delgado D, Rakowski H, et al. Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics. J Cardiovasc Magn Reson. 2017;19:61. https://doi.org/10.1186/s12968-017-0376-0.CrossRefPubMedPubMedCentral

[65]

Illman JE, Arunachalam SP, Arani A, Chang IC-Y, Glockner JF, Dispenzieri A, et al. MRI feature tracking strain is prognostic for all-cause mortality in AL amyloidosis. Amyloid. 2018;25:101–8. https://doi.org/10.1080/13506129.2018.1465406.CrossRefPubMedPubMedCentral

[66]

Ridouani F, Damy T, Tacher V, Derbel H, Legou F, Sifaoui I, et al. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson. 2018;20:58. https://doi.org/10.1186/s12968-018-0478-3.CrossRefPubMedPubMedCentral

[67]

Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol. 2018;71:2919–31. https://doi.org/10.1016/j.jacc.2018.03.536.CrossRefPubMed

[68]

Musumeci MB, Cappelli F, Russo D, Tini G, Canepa M, Melandri A et al. Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. JACC Cardiovasc Imaging. Epub ahead of print 18 December 2019. https://doi.org/10.1016/j.jcmg.2019.10.015.

[69]

Wan K, Li W, Sun J, Xu Y, Wang J, Liu H, et al. Regional amyloid distribution and impact on mortality in light-chain amyloidosis: a T1 mapping cardiac magnetic resonance study. Amyloid. 2019;26:45–51. https://doi.org/10.1080/13506129.2019.1578742.CrossRefPubMed

[70•.

] Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, et al. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2019. https://doi.org/10.1016/j.jcmg.2019.03.026This large study highlights the ability of native T1 for the diagnosis of cardiac amyloidosis, suggesting a possible diagnostic alghorithm to be used in patients in which adolinium contrast media cannot be administered.

[71]

Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2018. https://doi.org/10.1016/j.jcmg.2018.02.006.

[72]

Lin L, Li X, Feng J, Shen K-N, Tian Z, Sun J, et al. The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis. J Cardiovasc Magn Reson. 2018;20:2. https://doi.org/10.1186/s12968-017-0419-6.CrossRefPubMedPubMedCentral

[73]

Yilmaz A. The “native T1 versus extracellular volume fraction paradox” in cardiac amyloidosis: answer to the million-dollar question? JACC Cardiovasc Imaging. 2019;12:820–2. https://doi.org/10.1016/j.jcmg.2018.03.029.CrossRefPubMed

[74]

Da Nam B, Kim SM, Jung HN, Kim Y, Choe YH. Comparison of quantitative imaging parameters using cardiovascular magnetic resonance between cardiac amyloidosis and hypertrophic cardiomyopathy: inversion time scout versus T1 mapping. Int J Card Imaging. 2018;34:1769–77. https://doi.org/10.1007/s10554-018-1385-2.CrossRef

[75]

Boynton SJ, Geske JB, Dispenzieri A, Syed IS, Hanson TJ, Grogan M, et al. LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9:680–6. https://doi.org/10.1016/j.jcmg.2015.10.027.CrossRefPubMed

[76]

Raina S, Lensing SY, Nairooz RS, Pothineni NVK, Hakeem A, Bhatti S, et al. Prognostic value of late gadolinium enhancement CMR in systemic amyloidosis. JACC Cardiovasc Imaging. 2016;9:1267–77. https://doi.org/10.1016/j.jcmg.2016.01.036.CrossRefPubMed

[77]

Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132:1570–9. https://doi.org/10.1161/CIRCULATIONAHA.115.016567.CrossRefPubMedPubMedCentral

[78]

Dungu JN, Valencia O, Pinney JH, Gibbs SDJ, Rowczenio D, Gilbertson JA, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7:133–42. https://doi.org/10.1016/J.JCMG.2013.08.015.CrossRefPubMed

[79]

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–16. https://doi.org/10.1056/NEJMoa1805689.CrossRefPubMed

[80]

Shintani Y, Okada A, Morita Y, Hamatani Y, Amano M, Takahama H, et al. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy. ESC Heart Fail. 2019;6:232–6. https://doi.org/10.1002/ehf2.12382.CrossRefPubMed

[81]

Mangion K, McDowell K, Mark PB, Rutherford E. Characterizing cardiac involvement in chronic kidney disease using CMR-a systematic review. Curr Cardiovasc Imaging Rep. 2018;11:2. https://doi.org/10.1007/s12410-018-9441-9.CrossRefPubMedPubMedCentral

[82]

Shamseddin MK, Parfrey PS. Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol. 2011;7:145–54. https://doi.org/10.1038/nrneph.2010.191.CrossRefPubMed

[83]

Park M, Hsu C, Li Y, Mishra RK, Keane M, Rosas SE, et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol. 2012;23:1725–34. https://doi.org/10.1681/ASN.2012020145.CrossRefPubMedPubMedCentral

[84]

Wald R, Goldstein MB, Perl J, Kiaii M, Yuen D, Wald RM, et al. The association between conversion to in-centre nocturnal hemodialysis and left ventricular mass regression in patients with end-stage renal disease. Can J Cardiol. 2016;32:369–77. https://doi.org/10.1016/j.cjca.2015.07.004.CrossRefPubMed

[85]

Arnold R, Schwendinger D, Jung S, Pohl M, Jung B, Geiger J, et al. Left ventricular mass and systolic function in children with chronic kidney disease—comparing echocardiography with cardiac magnetic resonance imaging. Pediatr Nephrol. 2016;31:255–65. https://doi.org/10.1007/s00467-015-3198-z.CrossRefPubMed

[86]

Edwards NC, Moody WE, Yuan M, Hayer MK, Ferro CJ, Townend JN, et al. Diffuse interstitial fibrosis and myocardial dysfunction in early chronic kidney disease. Am J Cardiol. 2015;115:1311–7. https://doi.org/10.1016/j.amjcard.2015.02.015.CrossRefPubMed

[87•.

] Rutherford E, Talle MA, Mangion K, Bell E, Rauhalammi SM, Roditi G, et al. Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping. Kidney Int. 2016;90:845–52. https://doi.org/10.1016/j.kint.2016.06.014Comprehensive study describing morphologic and functional CMR findings, including interstitial fibrosis and cardiac mechanics assessment, in severe CKD patients. CrossRefPubMedPubMedCentral

[88]

Gong IY, Al-Amro B, Prasad GVR, Connelly PW, Wald RM, Wald R, et al. Cardiovascular magnetic resonance left ventricular strain in end-stage renal disease patients after kidney transplantation. J Cardiovasc Magn Reson. 2018;20:83. https://doi.org/10.1186/s12968-018-0504-5.CrossRefPubMedPubMedCentral

[89]

Hayer MK, Radhakrishnan A, Price AM, Baig S, Liu B, Ferro CJ, et al. Early effects of kidney transplantation on the heart - a cardiac magnetic resonance multi-parametric study. Int J Cardiol. 2019;293:272–7. https://doi.org/10.1016/j.ijcard.2019.06.007.CrossRefPubMedPubMedCentral

[90]

Kotecha T, Martinez-Naharro A, Yoowannakul S, Lambe T, Rezk T, Knight DS, et al. Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. Sci Rep. 2019;9:1388. https://doi.org/10.1038/s41598-018-37845-4.CrossRefPubMedPubMedCentral

[91]

Arcari L, Hinojar R, Carr-White G, Zainal H, Zhou H, Vasques M, et al. 24Excess of myocardial water and fibrosis define myocardial hypertrophy in uremic but not in hypertrophic cardiomyopathy - TrueTypeCKD study. Eur Heart J Cardiovasc Imaging. 2019;20. https://doi.org/10.1093/ehjci/jez111.002.

[92]

Aoki J, Ikari Y, Nakajima H, Mori M, Sugimoto T, Hatori M, et al. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int. 2005;67:333–40. https://doi.org/10.1111/J.1523-1755.2005.00086.X.CrossRefPubMed

[93]

Chen M, Arcari L, Engel J, Freiwald T, Platschek S, Zhou H, et al. Aortic stiffness is independently associated with interstitial myocardial fibrosis by native T1 and accelerated in the presence of chronic kidney disease. IJC Heart Vasc. 2019;24:100389. https://doi.org/10.1016/J.IJCHA.2019.100389.CrossRef

[94]

Hayer MK, Price AM, Liu B, Baig S, Ferro CJ, Townend JN, et al. Diffuse myocardial interstitial fibrosis and dysfunction in early chronic kidney disease. Am J Cardiol. 2018;121:656–60. https://doi.org/10.1016/j.amjcard.2017.11.041.CrossRefPubMedPubMedCentral

[95]

Contti MM, Barbosa MF, del Carmen Villanueva Mauricio A, Nga HS, Valiatti MF, Takase HM, et al. Kidney transplantation is associated with reduced myocardial fibrosis. A cardiovascular magnetic resonance study with native T1 mapping. J Cardiovasc Magn Reson. 2019;21:21. https://doi.org/10.1186/s12968-019-0531-x.CrossRefPubMedPubMedCentral

[96]

•• https://car.ca/news/new-car-guidelines-use-gadolinium-based-contrast-agents-kidney-disease/. Last Accessed November 4th 2019. Guidelines by the Canadian Association of Radiologists that explicitly allow macrocyclic gadolinium contrast media to be administered in patients with severe CKD, at the lowest dose required and when clinically indicated.

[97]

Mohandas R, Segal MS, Huo T, Handberg EM, Petersen JW, Johnson BD, et al. Renal function and coronary microvascular dysfunction in women with symptoms/signs of ischemia. PLoS One. 2015;10:e0125374. https://doi.org/10.1371/journal.pone.0125374.CrossRefPubMedPubMedCentral

[98]

Rutherford E, Weir-McCall JR, Patel RK, Houston JG, Roditi G, Struthers AD, et al. Research cardiac magnetic resonance imaging in end stage renal disease - incidence, significance and implications of unexpected incidental findings. Eur Radiol. 2017;27:315–24. https://doi.org/10.1007/s00330-016-4288-4.CrossRefPubMed

[99]

Pelliccia A, Caselli S, Sharma S, Basso C, Bax JJ, Corrado D, et al. European Association of Preventive Cardiology (EAPC) and European Association of Cardiovascular Imaging (EACVI) joint position statement: recommendations for the indication and interpretation of cardiovascular imaging in the evaluation of the athlete’s heart. Eur Heart J. 2018;39:1949–69. https://doi.org/10.1093/eurheartj/ehx532.CrossRefPubMed

[100•.

] Luijkx T, Cramer MJ, Prakken NHJ, Buckens CF, Mosterd A, Rienks R, et al. Sport category is an important determinant of cardiac adaptation: an MRI study. Br J Sports Med. 2012;46:1119–24. https://doi.org/10.1136/bjsports-2011-090520This study demonstrates that there is a balanced cardiac adaptation in term of left/right ventricular volume and LV volume/wall mass and that sport category has a strong impact on cardiac adaptation. CrossRefPubMed

[101]

Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349:1064–75. https://doi.org/10.1056/NEJMra022783.CrossRefPubMed

[102]

Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med. 1991;324:295–301. https://doi.org/10.1056/NEJM199101313240504.CrossRefPubMed

[103]

Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes: insights into methods for distinguishing athlete’s heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation. 1995;91:1596–601. https://doi.org/10.1161/01.CIR.91.5.1596.CrossRefPubMed

[104]

Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, Gibson CM, Lesser JR, et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol. 2008;101:668–73. https://doi.org/10.1016/j.amjcard.2007.10.032.CrossRefPubMed

[105]

Gruner C, Chan RH, Crean A, Rakowski H, Rowin EJ, Care M, et al. Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Eur Heart J. 2014;35:2706–13. https://doi.org/10.1093/eurheartj/ehu154.CrossRefPubMed

[106]

Maron MS, Hauser TH, Dubrow E, Horst TA, Kissinger KV, Udelson JE, et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol. 2007;100:1293–8. https://doi.org/10.1016/j.amjcard.2007.05.061.CrossRefPubMed

[107]

Maron MS, Rowin EJ, Lin D, Appelbaum E, Chan RH, Gibson CM, et al. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2012;5:441–7. https://doi.org/10.1161/CIRCIMAGING.112.972760.CrossRefPubMed

[108•.

] McDiarmid AK, Swoboda PP, Erhayiem B, Lancaster RE, Lyall GK, Broadbent DA, et al. Athletic cardiac adaptation in males is a consequence of elevated myocyte mass. Circ Cardiovasc Imaging. 2016;9. https://doi.org/10.1161/CIRCIMAGING.115.003579This study demonstrated with T1 mapping that increased left ventricular mass is due to an expansion of the cellular compartment while the extracellular volume becomes relatively smaller.

[109]

Treibel TA, Kozor R, Menacho K, Castelletti S, Bulluck H, Rosmini S, et al. Left ventricular hypertrophy revisited: cell and matrix expansion have disease-specific relationships. Circulation. 2017;136:2519–21. https://doi.org/10.1161/CIRCULATIONAHA.117.029895.CrossRefPubMed

[110]

Swoboda PP, Garg P, Levelt E, Broadbent DA, Zolfaghari-Nia A, Foley AJR, et al. Regression of left ventricular mass in athletes undergoing complete detraining is mediated by decrease in intracellular but not extracellular compartments. Circ Cardiovasc Imaging. 2019;12. https://doi.org/10.1161/circimaging.119.009417.

[111]

Swoboda PP, McDiarmid AK, Erhayiem B, Broadbent DA, Dobson LE, Garg P, et al. Assessing myocardial extracellular volume by T1 mapping to distinguish hypertrophic cardiomyopathy from Athlete’s heart. J Am Coll Cardiol. 2016;67:2189–90. https://doi.org/10.1016/j.jacc.2016.02.054.CrossRefPubMed

[112]

Zorzi A, Marra MP, Rigato I, De Lazzari M, Susana A, Niero A, et al. Nonischemic left ventricular scar as a substrate of life-threatening ventricular arrhythmias and sudden cardiac death in competitive athletes. Circ Arrhythm Electrophysiol. 2016;9. https://doi.org/10.1161/CIRCEP.116.004229.

[113]

Hagège A, Réant P, Habib G, Damy T, Barone-Rochette G, Soulat G, et al. Fabry disease in cardiology practice: literature review and expert point of view. Arch Cardiovasc Dis. 2019;112:278–87. https://doi.org/10.1016/j.acvd.2019.01.002.CrossRefPubMed

[114]

Perry R, Shah R, Saiedi M, Patil S, Ganesan A, Linhart A, et al. The role of cardiac imaging in the diagnosis and management of Anderson-Fabry disease. JACC Cardiovasc Imaging. 2019;12:1230–42. https://doi.org/10.1016/j.jcmg.2018.11.039.CrossRefPubMed

[115]

Nordin S, Kozor R, Bulluck H, Castelletti S, Rosmini S, Abdel-Gadir A, et al. Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy. J Am Coll Cardiol. 2016;68:1707–8. https://doi.org/10.1016/j.jacc.2016.07.741.CrossRefPubMed

[116]

Deva DP, Hanneman K, Li Q, Ng MY, Wasim S, Morel C, et al. Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease. J Cardiovasc Magn Reson. 2016;18:14. https://doi.org/10.1186/s12968-016-0233-6.CrossRefPubMedPubMedCentral

[117]

Hsu T-R, Hung S-C, Chang F-P, Yu W-C, Sung S-H, Hsu C-L, et al. Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation. J Am Coll Cardiol. 2016;68:2554–63. https://doi.org/10.1016/j.jacc.2016.09.943.CrossRefPubMed

[118]

Valbuena-López S, Eiros R, Dalmau R, Guzmán G. Contemporary view of magnetic resonance imaging in Fabry disease. Curr Cardiovasc Imaging Rep. 2019;12:1–8. https://doi.org/10.1007/s12410-019-9498-0.CrossRef

[119]

Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–87. https://doi.org/10.1093/eurheartj/ehx350.CrossRefPubMedPubMedCentral

[120]

Rodrigues JCL, Amadu AM, Dastidar AG, Hassan N, Lyen SM, Lawton CB, et al. Prevalence and predictors of asymmetric hypertensive heart disease: insights from cardiac and aortic function with cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging. 2016;17:1405–13. https://doi.org/10.1093/ehjci/jev329.CrossRefPubMed

[121]

Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, et al. Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol. 2015;65:1668–82. https://doi.org/10.1016/j.jacc.2015.03.043.CrossRefPubMedPubMedCentral

[122]

Duca F, Kammerlander AA, Zotter-Tufaro C, Aschauer S, Schwaiger ML, Marzluf BA, et al. Interstitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction. Circ Cardiovasc Imaging. 2016;9. https://doi.org/10.1161/CIRCIMAGING.116.005277.

[123]

Rommel KP, Von Roeder M, Latuscynski K, Oberueck C, Blazek S, Fengler K, et al. Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2016;67:1815–25. https://doi.org/10.1016/j.jacc.2016.02.018.CrossRefPubMed

[124]

Pathan F, Puntmann VO, Nagel E. Role of cardiac magnetic resonance in heart failure with preserved ejection fraction. Curr Cardiovasc Imaging Rep. 2018;11:10–1. https://doi.org/10.1007/s12410-018-9450-8.CrossRef

Title: CMR in Hypertrophic Cardiac Conditions—an Update
Authors: Michalis Kolentinis
Viviana Maestrini
Eleftherios Vidalakis
Sara Cimino
Luca Arcari
Publication date: 01-04-2020
Publisher: Springer US
Keywords: Edema
Cardiac Amyloidosis
Chronic Kidney Disease
Published in: Current Cardiovascular Imaging Reports / Issue 4/2020
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-020-9533-1

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

CMR in Hypertrophic Cardiac Conditions—an Update

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page